When was Angle founded?

Angle was founded in 1994 and raised its 1st funding round 21 years after it was founded.

Where is Angle located?

Angle is headquartered in Surrey, Canada.

Who is the current CEO of Angle?

Andrew Newland of Angle. They are also an angel investors in 1 startup.

How many employees does Angle have?

As of Aug 31, 2026, the latest employee count at Angle is 117.

Is Angle a funded company?

Angle is a funded company, having raised an undisclosed amount across 6 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Feb 26, 2015.

When was the latest funding round of Angle?

Angle's latest funding was a $***** Post IPO round on Jul 15, 2022, with participation from 0 investor.

Where does Angle rank among its competitors?

Angle ranks 6th amongst 140 active competitors, of which 55 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Delfi Diagnostics, which secured $34.3M in Dec, 2025.

Who are the top competitors of Angle?

Angle's top competitors include Freenome Health, Delfi Diagnostics and Personalis. Among them, Delfi Diagnostics secured the most recent funding round in December, 2025.

Angle - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of cancer cell capture and analysis equipment. The company uses liquid biopsy technology and develops Parsortix PC1 Clinical System a medical device for the capture and harvest of intact circulating tumor cells (CTCs) from metastatic breast cancer (MBC) patient blood for user-validated analysis.

Website: angleplc.com
Social

Key Metrics

Founded Year

1994

Location

Surrey, Canada

Stage

Public

Latest Funding Round

Post IPO, Jul 15, 2022, $*****

Investors

WG Partners & 2 more

Ranked

6^th among 140 active competitors

Employee Count

117 as on Aug 31, 2026

Investment & Acquisitions

Axela & 1 more

Similar Companies

Freenome Health & 160 more

Exit Details

Public

View Angle's full profile

Angle got listed on Mar 17, 2004.

Click here to take a look at Angle's IPO in detail

Angle has raised funding over 6 rounds. Its first funding round was on Feb 26, 2015. Angle has 3 institutional investors.

Here is the list of recent funding rounds of Angle:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 15, 2022	2144489	Post IPO	8414155	2195705	8180425	1897165
Oct 30, 2020	2787587	Post IPO	4140524	2035007	3626897	8798001
Jun 25, 2018	5074236	Post IPO	9130167	1974527	8886201	2431744

Access funding benchmarks and valuations. Sign up today!

View details of Angle's funding rounds and investors

The founders of Angle is Andrew Newland.

Here are the details of Angle's key team members:

Andrew Newland: Founder & CEO of Angle. They are also an angel investor in 1 startup.
Contact Info: 1 email address

View details of Angle's Founder profiles and Board Members

Angle's employee count trend

Angle has 117 employees as of Aug 26. Here is Angle's employee count trend over the years:

Uncover Angle's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Angle include Freenome Health, Delfi Diagnostics and Personalis. Here is the list of Top 10 competitors of Angle, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Freenome Health 2014, United States, Series E	Provider of a deep learning platform for detecting circulating cancer-related markers	$1.35B	Perceptive Advisors, RA Capital Management ... & 65 others	66/100
2nd	Delfi Diagnostics 2019, Baltimore (United States), Series B	Provider of DNA sequencing for cancer detection	$332M	DFJ Growth, Orbimed & 19 others	64/100
3rd	Personalis 2011, Menlo Park (United States), Acquired	Provider of genomic sequencing and diagnosis software for the healthcare industry	$87.3M	Abingworth, Lightspeed Venture Partners & 5 others	61/100
4th	Predicta Biosciences 2023, Boston (United States), Series A	Provider of diagnostic and therapeutic products for oncology	$28.6M	Engine Ventures, Myeloma Solutions Fund & 7 others	59/100
5th	Xcell Biosciences 2012, San Francisco (United States), Series B	Developer of cell culture analysis device for cancer research	$40.9M	Casdin Capital, HBM Genomics & 10 others	59/100
6th	Angle 1994, Surrey (Canada), Public	Developer of cancer cell capture and analysis equipment	-	WG Partners, Mercia & 1 others	57/100
7th	Datar Genetics 1992, Nashik (India), Early Stage	Provider of liquid biopsy-based cancer diagnostic test	$2.98M	Alkemi Growth Capital, Brand Capital & 14 others	56/100
8th	Tethis 2004, Milan (Italy), Series A	Provider of automated solutions for in liquid biopsy	$15.3M	sanpaolope.com, Indaco Venture Partners & 5 others	55/100
9th	Strata Oncology 2015, Ann Arbor (United States), Series C	Precision oncology company enabling smarter cancer treatment through advanced biomarker algorithms	$139M	Wellington, Baird Capital & 8 others	55/100
10th	Epredia 2019, United Kingdom, Unfunded	Developer of in-vitro diagnostic test for cancer	-	-	55/100